Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results.
2004 Apr 27
Journal Article
Authors:
Burke, G.W.;
Kaufman, D.B.;
Millis, M.;
Gaber, O.;
Johnson, C.P.;
Sutherland, D.E.R.;
Punch, J.D.;
Kahan, B.D.;
Schweitzer, E.;
Langnas, A.;
Perkins, J.;
Scandling, J.;
Concepcion, W.;
Stegall, M.D.;
Schulak, J.A.;
Gores, P.F.;
Benedetti, E.;
Danovitch, G.;
Henning, A.K.;
Bartucci, M.R.;
Smith, S.;
Fitzsimmons, W.E.
Secondary:
Transplantation
Volume:
77
Pagination:
1269-75
Issue:
8
PMID:
15114097
DOI:
10.1097/01.tp.0000123903.12311.36
Keywords:
Antibodies, Monoclonal; Antilymphocyte Serum; Female; Graft Survival; Humans; Immunosuppressive Agents; kidney transplantation; Lymphocyte Depletion; Male; Pancreas Transplantation; Prospective Studies; Receptors, Interleukin-2; Time Factors
Abstract:
BACKGROUND: Historically, antibody induction has been used because of the higher immunologic risk of graft loss or rejection observed in simultaneous pancreas and kidney (SPK) transplantation compared with kidney transplantation alone. This trial was designed to assess the effect of antibody induction in SPK transplant recipients receiving tacrolimus, mycophenolate mofetil, and corticosteroids. Induction agents included T-cell-depleting and interleukin-2 receptor antibodies.METHODS: A total of 174 SPK transplant recipients were enrolled in a prospective, open-label, multi-center study. They were randomized to induction (n=87) or non-induction (n=87) groups and followed for 3 years.RESULTS: At 3 years, actual patient (94.3% and 89.7%) and pancreas (75.9% and 75.9%) survivals were similar between the induction and non-induction groups, respectively. Actual kidney survival was similar at 1 and 2 years, but at 3 years, it was significantly better in the induction group compared with the non-induction group (92% vs. 81.6%; P =0.04). At 3 years, median serum creatinine and hemoglobin A1C were similar between the induction and non-induction groups (1.35 mg/dL and 1.20 mg/dL, 5.4% and 5.5%, respectively). Three-year cumulative incidence of biopsy-confirmed, treated acute kidney rejection in the induction and non-induction groups was 19.5% and 27.5% (P =0.14), respectively, with odds 4.6 times greater in African Americans regardless of treatment (P =0.004). Significantly higher rates of cytomegalovirus (CMV) viremia and CMV syndrome occurred in those receiving T-cell-depleting antibody induction (36.1%) when compared with those receiving anti-interleukin-2 receptor antibodies (2%) and non-induction (8.1%) (P <0.0001).CONCLUSIONS: Tacrolimus, mycophenolate mofetil, and corticosteroids resulted in excellent safety and efficacy in SPK transplant recipients. Actual 3-year kidney survival was significantly better in the induction group; however, CMV viremia and CMV syndrome rates were significantly higher in the T-cell-depleting antibody group. African Americans demonstrated a significantly greater risk of acute rejection despite antibody induction. Decisions regarding the use of induction therapy must weigh the risk of kidney graft loss or rejection against the risk of infection.
